<?xml version="1.0" encoding="UTF-8"?>
<mods xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.loc.gov/mods/v3" version="3.1" xsi:schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">
  <titleInfo>
    <title>CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges</title>
  </titleInfo>
  <name type="personal">
    <namePart>Xiaomin Zhang</namePart>
    <role>
      <roleTerm authority="marcrelator" type="text">creator</roleTerm>
    </role>
    <role>
      <roleTerm type="text">author.</roleTerm>
    </role>
  </name>
  <name type="personal">
    <namePart>Lingling Zhu</namePart>
    <role>
      <roleTerm type="text">author.</roleTerm>
    </role>
  </name>
  <name type="personal">
    <namePart>Hui Zhang</namePart>
    <role>
      <roleTerm type="text">author.</roleTerm>
    </role>
  </name>
  <name type="personal">
    <namePart>Shanshan Chen</namePart>
    <role>
      <roleTerm type="text">author.</roleTerm>
    </role>
  </name>
  <name type="personal">
    <namePart>Yang Xiao</namePart>
    <role>
      <roleTerm type="text">author.</roleTerm>
    </role>
  </name>
  <typeOfResource>text</typeOfResource>
  <genre authority="">Review articles.</genre>
  <originInfo>
    <place>
      <placeTerm type="code" authority="marccountry">xx</placeTerm>
    </place>
    <dateIssued encoding="marc">2022</dateIssued>
    <issuance>monographic</issuance>
  </originInfo>
  <language>
    <languageTerm authority="iso639-2b" type="code">eng</languageTerm>
  </language>
  <physicalDescription>
    <extent>1 online resource (1 article).</extent>
  </physicalDescription>
  <abstract>Chimeric antigen receptor T (CAR-T) cell therapy represents a major breakthrough in cancer treatment, and it has achieved unprecedented success in hematological malignancies, especially in relapsed/refractory (R/R) B cell malignancies. At present, CD19 and BCMA are the most common targets in CAR-T cell therapy, and numerous novel therapeutic targets are being explored. However, the adverse events related to CAR-T cell therapy might be serious or even life-threatening, such as cytokine release syndrome (CRS), CAR-T-cell-related encephalopathy syndrome (CRES), infections, cytopenia, and CRS-related coagulopathy. In addition, due to antigen escape, the limited CAR-T cell persistence, and immunosuppressive tumor microenvironment, a considerable proportion of patients relapse after CAR-T cell therapy. Thus, in this review, we focus on the progress and challenges of CAR-T cell therapy in hematological malignancies, such as attractive therapeutic targets, CAR-T related toxicities, and resistance to CAR-T cell therapy, and provide some practical recommendations.</abstract>
  <note type="statement of responsibility">Xiaomin Zhang; Lingling Zhu; Hui Zhang [and others].</note>
  <note>Publication type: Review article.</note>
  <note>Linked open-access copy: published version.</note>
  <note>Open access; no subscription required for the linked open-access version. Unrestricted online access star</note>
  <note xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://europepmc.org/articles/PMC9226391">Creative Commons Attribution (licence family recorded by the source; version not supplied in metadata). https://europepmc.org/articles/PMC9226391</note>
  <note>In English.</note>
  <subject>
    <topic>Hematological malignancies</topic>
  </subject>
  <subject>
    <topic>Combinatorial Therapy</topic>
  </subject>
  <subject>
    <topic>Antigen Escape</topic>
  </subject>
  <subject>
    <topic>Immunosuppressive Tumor Microenvironment</topic>
  </subject>
  <subject>
    <topic>Car-t Cell</topic>
  </subject>
  <subject>
    <topic>Car-t Related Toxicities</topic>
  </subject>
  <subject>
    <topic>B. Sc. Medical Laboratory Science</topic>
  </subject>
  <subject>
    <topic>UMUN open access collection</topic>
  </subject>
  <subject>
    <topic>hematology</topic>
  </subject>
  <relatedItem type="host">
    <titleInfo>
      <title>Frontiers in immunology</title>
    </titleInfo>
    <identifier type="issn">1664-3224</identifier>
    <part>
      <text>Vol. 13, (2022), pages/article 927153</text>
    </part>
  </relatedItem>
  <identifier type="uri">https://europepmc.org/articles/PMC9226391</identifier>
  <location>
    <url displayLabel="Read open-access publication">https://europepmc.org/articles/PMC9226391</url>
  </location>
  <accessCondition type="restrictionOnAccess">Open access; no subscription required for the linked open-access version.</accessCondition>
  <accessCondition type="useAndReproduction">Creative Commons Attribution (licence family recorded by the source; version not supplied in metadata).</accessCondition>
  <recordInfo>
    <recordContentSource authority="marcorg">local</recordContentSource>
    <recordCreationDate encoding="marc">261005</recordCreationDate>
    <recordChangeDate encoding="iso8601">20261005174905.0</recordChangeDate>
    <recordIdentifier source="local">UMUN-OA-20261005-MLS-056</recordIdentifier>
    <languageOfCataloging>
      <languageTerm authority="iso639-2b" type="code">eng</languageTerm>
    </languageOfCataloging>
  </recordInfo>
</mods>
